A Review on Teicoplanin Used as Alternative Drug to Treat the Novel Corona Virus (COVID – 19)
Anirban Adhikary, Kakoli Halder, Debmalya Ghosh, Snehansu Biswas, Indranil Chatterjee and Suman Kumar Nath
Journal Title:Acta Scientific Microbiology
In December 2019, another coronavirus, named SARS-CoV-2, has risen up out of China causing pneumonia episodes first in the Wuhan locale and have now spread overall in view of its plausible high transmission productivity. Because of the absence of pro-ductive and explicit medicines and the need to contain the pestilence, medicate repurposing has all the earmarks of being the best instrument to discover remedial arrangement. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have demonstrated viability to restrain coronavirus in vitro. Teicoplanin, an anti-microbial used to treat staphylococci disease, recently demonstrated adequacy to hinder the principal phase of MERS coronavirus viral cycle in human cells. This action is preserved on the SARS-Cov-2, accordingly putting teicoplanin as an expected treatment for patients with this infection.